C4 therapeutics presents new preclinical data for cft1946 highlighting superior activity as a single agent to clinically approved braf inhibitor standard of care combinations at the american association for cancer research annual meeting 2024

Watertown, mass., april 08, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the american association for cancer research (aacr) annual meeting 2024 highlighting new preclinical data for cft1946 across multiple models of braf v600x mutant colorectal cancer (crc) and non-small cell lung cancer (nsclc), additional braf inhibitor (brafi)-resistant melanoma models, and an intracranial model of braf v600e metastatic melanoma.
CCCC Ratings Summary
CCCC Quant Ranking